Felypressin is a topic that has generated interest and debate in recent years. Known for its relevance in different aspects of society, this topic has captured the attention of experts and people interested in understanding its impact. As you delve deeper into Felypressin, new perspectives and questions arise that invite you to explore its many facets. This article seeks to offer a comprehensive view of Felypressin, addressing everything from its origins to its current implications. Through a detailed analysis and enriching reflections, it is intended to provide the reader with a broader and more enriching look at Felypressin.
![]() | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (February 2025) |
![]() | |
Names | |
---|---|
IUPAC name
1--pyrrolidine-2-carboxylic acid -amide
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.000.257 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C46H65N13O11S2 | |
Molar mass | 1040.22 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
Felypressin is a non-catecholamine vasoconstrictor that is chemically related to vasopressin, the posterior pituitary hormone. It is added to some local anaesthetics such as prilocaine in a concentration of 0.03 IU/ml. Felypressin is a Vasopressin 1 agonist, and will thus have effects at all Arginine vasopressin receptor 1As. It will, however, have its main physiological effects on vascular SMC's due to the form in which it is administered.
V1 receptors are found in various sites around the body. The major points include the CNS, Liver, Anterior Pituitary, Muscle (both vascular and non-vascular smooth muscle), and Platelets (CLAMP).
Another example of a V1 agonist is terlipressin - which is used in oesophageal varices.